Jones Mitchell Lawrence 4

What Happened

• Jones Mitchell Lawrence, Chief Medical Officer of Palisade Bio, received an award of 787,000 restricted stock units (RSUs) on February 9, 2026. The filing reports an acquisition price of $0.00 because this is a grant of derivative awards (RSUs), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-09; Filing date: 2026-02-11 (filed within the typical 2‑business‑day Form 4 window).
• Award type/code: A (Grant/Award); instrument: Restricted Stock Units (derivative).
• Reported acquisition price: $0.00 (typical for RSU grants).
• Shares owned following the transaction: not specified in the provided filing.
• Notable footnotes:
  • F1: Each RSU is a contingent right to one share; until the company has sufficient shares reserved under its 2021 Equity Incentive Plan, RSUs may be settled in cash.
  • F2: Vesting schedule: 1/6 of the RSUs vest on July 6, 2026 and then quarterly over the following 10 quarters, subject to continuous service.

Context

• RSU grants are compensation awards and are not direct purchases or sales; they convert to shares (or cash, per F1) upon vesting. This transaction is informational about executive compensation and potential future share issuance rather than an immediate market buy/sell signal.